Close
Almac
Achema middle east

Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

July 27, 2023

Bio-Asia Taiwan Exhibition

Taipei, Taiwan

Bora has been awarded “Outstanding Company of the Year” by an independent panel of international judges during Bio-Asia Taiwan exhibit taking place in Taipei, Taiwan July 24-26, 2023. Bora was chosen from a short list of several candidates for its demonstrated leadership in the Taiwan Biopharma industry.

Bobby Sheng said; “Our team’s focused dedication to excellence in quality and customer service continues to be acknowledged by our clients and in BioPharma industry. I’m especially proud of our biologic subsidiary, Bora Biologics, for growing at such a rapid pace and being recognized in the Biopharma community.” 

Bora is currently the only CDMO in Taiwan that has a leading position in both small and large molecules with 6 manufacturing sites with over 70 Billion NTD market cap.

https://boracdmo.com/news-and-events/bora-pharmaceuticals-is-awarded-outstanding-company-of-the-year-at-bio-asia-taiwan-2023/

Company: BORA PHARMACEUTICAL SERVICES INC.


Bora Pharmaceuticals and our group of companies is a publicly-traded company on the Taiwan Stock Exchange (6472). We are Taiwan's largest CDMO with a 50-year history in the Pharmaceutical Industry. We supply drugs to over 100 countries in the world, including the US/Canada, EU, Southeast Asia, Middle East, and South and Central America. We provide outsourced R&D, CDMO, and CMO services for global pharmaceutical companies around the world.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »